Quick Answer
Orchestra BioMed Holdings, Inc. reported Diluted EPS of $1.11 per share (loss) for fiscal year 2025.
Orchestra BioMed Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.11 | +33.1% |
| 2024 | -$1.66 | -12.2% |
| 2023 | -$1.48 | +33.9% |
| 2022 | -$2.24 | -11100.0% |
| 2021 | -$0.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | +2.4% | +20.0% |
| June 30, 2025 | -$0.50 | -11.1% | -2.0% |
| March 31, 2025 | -$0.49 | -28.9% | -19.5% |
| September 30, 2024 | -$0.41 | -7.9% | +8.9% |
| June 30, 2024 | -$0.45 | -28.6% | -18.4% |
| March 31, 2024 | -$0.38 | +5.0% | +0.0% |
| September 30, 2023 | -$0.38 | +25.5% | -8.6% |
| June 30, 2023 | -$0.35 | +54.5% | +12.5% |
- Orchestra BioMed Holdings, Inc. showed an increase of +33.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Orchestra BioMed Holdings, Inc.’s diluted eps has declined by 5450.0% (from $0.02 per share (loss) to $1.11 per share (loss)).
- The most recent figure is from Orchestra BioMed Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: